Asset: LY6G6D-targeted antibodies
Current Stage: IND, etc.
Indication: Advanced malignant solid tumors (primarily colorectal cancer)
Highlights:
(1) Have first-in-class (FIC) and best-in-class (BIC) potential.
(2) Show an exceptionally wide therapeutic window as validated in cynomolgus monkey DRF studies, with no observable liver toxicity even at high doses.
(3) Deliver robust anti-tumor efficacy in preclinical solid tumor models, including potent single-agent activity with high rates of complete tumor regression (CR).
(4) Exhibit prominent synergistic anti-tumor effects when combined with chemotherapy and PD-1/PD-L1 monoclonal antibodies.
(5) Backed by strong intellectual property (IP) protection.
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
